Series B
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain
Tune Therapeutics Secures $175M in Series B Funding to Advance Epigenome Editing Programs
Epigenome editing, Tune Therapeutics, Series B funding, Hepatitis B treatment, Gene therapy, Biotech investment
XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy
XyloCor Therapeutics, Series B funding, cardiovascular gene therapy, XC001, refractory angina, CABG, clinical trials
Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy
Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion
Cradle Bio Secures $73M Series B Funding to Revolutionize AI-Driven Protein Engineering
AI-powered protein engineering, Cradle Bio, Series B funding, pharmaceuticals, diagnostics, biotech startup
Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data
Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides
AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy
AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation
Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment